JCI Insight. 2022 Jun 8;7(11):e159422. doi: 10.1172/jci.insight.159422.
Secondary infections are frequent complications of viral respiratory infections, but the potential consequence of SARS-CoV-2 coinfection with common pulmonary pathogens is poorly understood. We report that coinfection of human ACE2-transgenic mice with sublethal doses of SARS-CoV-2 and Streptococcus pneumoniae results in synergistic lung inflammation and lethality. Mortality was observed regardless of whether SARS-CoV-2 challenge occurred before or after establishment of sublethal pneumococcal infection. Increased bacterial levels following coinfection were associated with alveolar macrophage depletion, and treatment with murine GM-CSF reduced numbers of lung bacteria and pathology and partially protected from death. However, therapeutic targeting of IFNs, an approach that is effective against influenza coinfections, failed to increase survival. Combined vaccination against both SARS-CoV-2 and pneumococci resulted in 100% protection against subsequent coinfection. The results indicate that when seasonal respiratory infections return to prepandemic levels, they could lead to an increased incidence of lethal COVID-19 superinfections, especially among the unvaccinated population.
继发感染是病毒性呼吸道感染的常见并发症,但人们对 SARS-CoV-2 与常见肺部病原体合并感染的潜在后果知之甚少。我们报告称,亚致死剂量的 SARS-CoV-2 与肺炎链球菌合并感染人类 ACE2 转基因小鼠会导致协同性肺部炎症和致死性。无论 SARS-CoV-2 攻击是在建立亚致死性肺炎链球菌感染之前还是之后发生,均观察到死亡率。合并感染后细菌水平增加与肺泡巨噬细胞耗竭有关,用鼠 GM-CSF 治疗可减少肺部细菌数量和病理学,并部分保护免受死亡。然而,针对流感合并感染有效的 IFN 治疗方法未能提高生存率。针对 SARS-CoV-2 和肺炎球菌的联合疫苗接种可实现对随后合并感染的 100%保护。研究结果表明,当季节性呼吸道感染恢复到大流行前水平时,它们可能导致 COVID-19 继发感染的发病率增加,尤其是在未接种疫苗的人群中。